TNFRSF12A and Miyoshi myopathy: In vitro, the combination of BZ + FINM with WJ-MSCs-mediated secretion of TRAIL markedly reduces the viability of the different MM cell lines, with statistically significant lower cell viability compared to single treatments against RPMI 8226 and MM1.S, but not against U266, most likely due to its low expression of CD266 after treatment with BZ.